We have 6 of 29 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
This Viewpoint evaluates the present relevance of Response Evaluation Criteria in Solid Tumors (RECIST) as cancer therapeutics have evolved beyond cytotoxic chemotherapy in assessing treatment outcomes.
Summary Tumour-agnostic immunotherapy has reshaped precision oncology by showing that treatment benefit can, in selected settings, be predicted by a shared biological state rather than anatomical origin. Microsatellite instability-high or mismatch repair-deficient cancer is the clearest example, with durable responses...
D dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab were tolerated and preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
Ulixertinib had no demonstrable evidence of clinical activity in this small, heavily pretreated population of patients with tumors harboring BRAF fusions, or with non-V600E, non-V600K BRAF mutations.
The TRACK trial provides a scalable decentralized model for equitable access to precision medicine for patients with rare cancers while simultaneously generating data to drive a better understanding of rare cancers that otherwise may have limited treatment options.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
